A novel and selective fluorescent ligand for the study of adenosine A2B receptors

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacology Research & Perspectives Pub Date : 2024-06-21 DOI:10.1002/prp2.1223
Foteini Patera, Sarah J. Mistry, Nicholas D. Kindon, Eleonora Comeo, Joelle Goulding, Barrie Kellam, Laura E. Kilpatrick, Hester Franks, Stephen J. Hill
{"title":"A novel and selective fluorescent ligand for the study of adenosine A2B receptors","authors":"Foteini Patera, Sarah J. Mistry, Nicholas D. Kindon, Eleonora Comeo, Joelle Goulding, Barrie Kellam, Laura E. Kilpatrick, Hester Franks, Stephen J. Hill","doi":"10.1002/prp2.1223","DOIUrl":null,"url":null,"abstract":"Fluorescent ligands have proved to be powerful tools in the study of G protein‐coupled receptors in living cells. Here we have characterized a new fluorescent ligand PSB603‐BY630 that has high selectivity for the human adenosine A<jats:sub>2B</jats:sub> receptor (A<jats:sub>2B</jats:sub>R). The A<jats:sub>2B</jats:sub>R appears to play an important role in regulating immune responses in the tumor microenvironment. Here we have used PSB603‐BY630 to monitor specific binding to A<jats:sub>2B</jats:sub>Rs in M1‐ and M2‐like macrophages derived from CD14+ human monocytes. PSB603‐BY630 bound with high affinity (18.3 nM) to nanoluciferase‐tagged A<jats:sub>2B</jats:sub>Rs stably expressed in HEK293G cells. The ligand exhibited very high selectivity for the A<jats:sub>2B</jats:sub>R with negligible specific‐binding detected at NLuc‐A<jats:sub>2A</jats:sub>R, NLuc‐A<jats:sub>1</jats:sub>R, or NLuc‐A<jats:sub>3</jats:sub>R receptors at concentrations up to 500 nM. Competition binding studies showed the expected pharmacology at A<jats:sub>2B</jats:sub>R with the A<jats:sub>2B</jats:sub>R‐selective ligands PSB603 and MRS‐1706 demonstrating potent inhibition of the specific binding of 50 nM PSB603‐BY630 to A<jats:sub>2B</jats:sub>R. Functional studies in HEK293G cells using Glosensor to monitor G<jats:sub>s</jats:sub>‐coupled cyclic AMP responses indicated that PSB603‐BY630 acted as a negative allosteric regular of the agonist responses to BAY 60–6583. Furthermore, flow cytometry analysis confirmed that PSB603‐BY630 could be used to selectively label endogenous A<jats:sub>2B</jats:sub>Rs expressed on human macrophages. This ligand should be an important addition to the library of fluorescent ligands which are selective for the different adenosine receptor subtypes, and will enable study of the role of A<jats:sub>2B</jats:sub>Rs on immune cells in the tumor microenvironment.","PeriodicalId":19948,"journal":{"name":"Pharmacology Research & Perspectives","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Research & Perspectives","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/prp2.1223","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Fluorescent ligands have proved to be powerful tools in the study of G protein‐coupled receptors in living cells. Here we have characterized a new fluorescent ligand PSB603‐BY630 that has high selectivity for the human adenosine A2B receptor (A2BR). The A2BR appears to play an important role in regulating immune responses in the tumor microenvironment. Here we have used PSB603‐BY630 to monitor specific binding to A2BRs in M1‐ and M2‐like macrophages derived from CD14+ human monocytes. PSB603‐BY630 bound with high affinity (18.3 nM) to nanoluciferase‐tagged A2BRs stably expressed in HEK293G cells. The ligand exhibited very high selectivity for the A2BR with negligible specific‐binding detected at NLuc‐A2AR, NLuc‐A1R, or NLuc‐A3R receptors at concentrations up to 500 nM. Competition binding studies showed the expected pharmacology at A2BR with the A2BR‐selective ligands PSB603 and MRS‐1706 demonstrating potent inhibition of the specific binding of 50 nM PSB603‐BY630 to A2BR. Functional studies in HEK293G cells using Glosensor to monitor Gs‐coupled cyclic AMP responses indicated that PSB603‐BY630 acted as a negative allosteric regular of the agonist responses to BAY 60–6583. Furthermore, flow cytometry analysis confirmed that PSB603‐BY630 could be used to selectively label endogenous A2BRs expressed on human macrophages. This ligand should be an important addition to the library of fluorescent ligands which are selective for the different adenosine receptor subtypes, and will enable study of the role of A2BRs on immune cells in the tumor microenvironment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于研究腺苷 A2B 受体的新型选择性荧光配体
事实证明,荧光配体是研究活细胞中 G 蛋白偶联受体的有力工具。在这里,我们鉴定了一种新型荧光配体 PSB603-BY630,它对人类腺苷 A2B 受体(A2BR)具有高选择性。A2BR 似乎在调节肿瘤微环境中的免疫反应方面发挥着重要作用。在这里,我们使用 PSB603-BY630 来监测与源自 CD14+ 人类单核细胞的 M1- 和 M2-like 巨噬细胞中 A2BR 的特异性结合。PSB603-BY630 与稳定表达在 HEK293G 细胞中的纳米荧光素酶标记的 A2BR 具有高亲和力(18.3 nM)。该配体对 A2BR 具有极高的选择性,在浓度高达 500 nM 时,与 NLuc-A2AR、NLuc-A1R 或 NLuc-A3R 受体的特异性结合可忽略不计。竞争结合研究显示了 A2BR 与 A2BR 选择性配体 PSB603 和 MRS-1706 的预期药理作用,显示了 50 nM PSB603-BY630 与 A2BR 特异性结合的强效抑制作用。在 HEK293G 细胞中使用 Glosensor 监测 Gs 偶联环 AMP 反应的功能研究表明,PSB603-BY630 是 BAY 60-6583 激动剂反应的负异位调节剂。此外,流式细胞仪分析证实,PSB603-BY630 可用于选择性标记人巨噬细胞上表达的内源性 A2BR。这种配体是对不同腺苷受体亚型具有选择性的荧光配体库的重要补充,有助于研究 A2BR 在肿瘤微环境中对免疫细胞的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
5.30
自引率
3.80%
发文量
120
审稿时长
20 weeks
期刊介绍: PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS
期刊最新文献
Hypothalamic cannabinoid signaling: Consequences for eating behavior. The evaluation of digital educational game use in pharmacology teaching process. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model-based approach. Effect of cyclosporin A on respiratory viral replication in fully differentiated ex vivo human airway epithelia. IS4-FAM, a fluorescent tool to study CXCR4 affinity and competitive antagonism in native cancer cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1